These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25163360)

  • 21. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
    Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
    Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.
    Fridén BE; Nilsson L
    Acta Obstet Gynecol Scand; 2005 Aug; 84(8):812-6. PubMed ID: 16026411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modified natural cycle versus controlled ovarian hyperstimulation IVF: a cost-effectiveness evaluation of three simulated treatment scenarios.
    Groen H; Tonch N; Simons AH; van der Veen F; Hoek A; Land JA
    Hum Reprod; 2013 Dec; 28(12):3236-46. PubMed ID: 24166594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme.
    Imoedemhe DA; Chan RC; Sigue AB; Pacpaco EL; Olazo AB
    Hum Reprod; 1991 Sep; 6(8):1088-91. PubMed ID: 1806566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.
    Sher G; Zouves C; Feinman M; Maassarani G
    Hum Reprod; 1995 Dec; 10(12):3107-9. PubMed ID: 8822423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature.
    Pinto E; Pinelo S; Osório M; Ferreira C; Serra H; Pires I; Barbosa A; Figueiredo H; Felgueira E; Tavares A
    Gynecol Endocrinol; 2012 Jul; 28(7):545-8. PubMed ID: 22439899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Is gonadotropin releasing hormone (GnRH) agonist trigger beneficial or deleterious?].
    Le Chatton M; Wittemer C; Schweitzer T; Lestrade F; Ragage JP
    Gynecol Obstet Fertil; 2016; 44(7-8):403-9. PubMed ID: 27451069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
    Atkinson P; Koch J; Ledger WL
    Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study.
    Griesinger G; Berndt H; Schultz L; Schultze-Mosgau A; Diedrich K; von Otte S
    Reprod Biomed Online; 2011 Feb; 22(2):133-9. PubMed ID: 21227753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase.
    Ben-Arie A; Weissman A; Shoham Z
    Hum Reprod; 1996 Jun; 11(6):1146-8. PubMed ID: 8671409
    [No Abstract]   [Full Text] [Related]  

  • 34. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization?
    Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y
    Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of serum albumin to prevent ovarian hyperstimulation syndrome?
    Sabatini L; Wilson C; al Shawaf T; Lower A; Grudzinskas JG
    Fertil Steril; 1997 Mar; 67(3):587-9. PubMed ID: 9091356
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of luteal phase ovulation induction and ultra-short gonadotropin-releasing hormone agonist protocols in older patients undergoing in vitro fertilization.
    Wang T; Sun Z; Lim JP; Yu Y
    Libyan J Med; 2019 Dec; 14(1):1597327. PubMed ID: 30935302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scientific evidence shows the need for a fresh approach to IVF.
    Nargund G
    Womens Health (Lond); 2015 Jan; 11(1):11-3. PubMed ID: 25581050
    [No Abstract]   [Full Text] [Related]  

  • 39. [Coasting: a response to excessive ovarian stimulation].
    Dechaud H; Anahory T; Aligier N; Arnal F; Humeau C; Hédon B
    Gynecol Obstet Fertil; 2000 Feb; 28(2):115-9. PubMed ID: 10758585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
    Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
    Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.